Skip to main content
. 2023 Nov 1;18(5):1231–1244. doi: 10.1002/1878-0261.13538

Table 3.

Clinical parameters based on ccfHPV DNA status.

ccfHPVpos primary surgery a (n = 4) ccfHPVneg primary surgery a (n = 46) ccfHPVpos primary surgery + adj b (n = 8) ccfHPVneg primary surgery + adj b (n = 14) ccfHPVpos primary oncology c (n = 54) ccfHPVneg primary oncology c (n = 13) P‐value d
Histology n (%) n (%) n (%) n (%) n (%) n (%) 1.00 e
SCC 3 (75.0) 26 (56.5) 7 (87.5) 8 (57.1) 50 (92.6) 12 (92.3)
AC 1 (25.0) 15 (32.6) 0 (0.0) 5 (35.7) 4 (7.4) 1 (7.7)
ASC 0 (0.0) 5 (10.9) 1 (12.5) 1 (7.1) 0 (0.0) 0 (0.0)
HPV genotype f n (%) n (%) n (%) n (%) n (%) n (%) 0.26 g
HPV16 3 (75.0) 20 (43.5) 4 (50.0) 3 (21.4) 32 (59.3) 5 (38.5)
HPV18 0 (0.0) 11 (23.9) 0 (0.0) 5 (35.7) 5 (9.3) 1 (7.7)
HPV31 0 (0.0) 2 (4.3) 0 (0.0) 1 (7.1) 3 (5.6) 1 (7.7)
HPV33 0 (0.0) 1 (2.2) 1 (12.5) 1 (7.1) 3 (5.6) 1 (7.7)
HPV45 1 (25.0) 4 (8.7) 1 (12.5) 1 (7.1) 4 (9.3) 3 (23.1)
Other 0 (0.0) 3 (6.5) 1 (12.5) 2 (14.3) 4 (9.3) 0 (0.0)
Multiple 0 (0.0) 5 (10.9) 1 (12.5) 1 (7.1) 3 (5.6) 2 (15.4)
Tumor size (mm) n (%) n (%) n (%) n (%) n (%) n (%) 0.61 h
< 20 1 (25.0) 32 (69.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
≥ 20 < 30 2 (50.0) 11 (23.9) 6 (75.0) 9 (64.3) 2 (3.7) 0 (0.0)
≥ 30 < 40 0 (0.0) 2 (4.3) 2 (25.0) 3 (21.4) 8 (14.8) 4 (30.7)
≥ 40 1 (25.0) 1 (2.2) 0 (0.0) 2 (14.3) 4 (7.4) 9 (69.2)
Mean ± SD 24.75 ± 11.3 17.3 ± 8.6 22.9 ± 6.6 28.6 ± 7.9 53.6 ± 19.2 49.9 ± 22.5
Median (IQR) 22 (7.75) 14.5 (11.5) 22 (5.25) 25 (10.5) 50.0 (22.3) 40.0 (24.0)
FIGO 2018 i n (%) n (%) n (%) n (%) n (%) n (%) 0.64 j
IA1 0 (0.0) 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
IA2 0 (0.0) 15 (32.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
IB1 1 (25.0) 15 (32.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
IB2 2 (50.0) 14 (30.4) 3 (37.5) 6 (42.9) 0 (0.0) 0 (0.0)
IB3 1 (25.0) 1 (2.2) 0 (0.0) 1 (7.1) 2 (3.7) 1 (7.7)
IIA1 0 (0.0) 0 (0.0) 1 (12.5) 1 (7.1) 0 (0.0) 0 (0.0)
IIB 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 21 (38.9) 5 (38.5)
IIIB 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (18.5) 0 (0.0)
IIIC1 0 (0.0) 0 (0.0) 3 (37.5) 6 (42.9) 26 (48.1) 6 (46.2)
IIIC2 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0) 3 (5.6) 0 (0.0)
IVA 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.9) 1 (7.7)
a

ccfHPVpos/neg patients referred for primary surgery, that is, primary surgery subgroup.

b

ccfHPVpos/neg patients referred for primary surgery and adjuvant oncological therapy, that is, primary surgery + adjuvant oncology subgroup.

c

ccfHPVpos/neg referred for primary oncological therapy, that is, primary oncology subgroup.

d

Statistical analyses were performed for the ccfHPVpos primary oncology subgroup vs. the ccfHPVneg primary oncology subgroup.

e

Fisher's exact test comparing SCCs vs. AC/ASCs.

f

HPV genotype according to analyses with the NGS HPV genotyping panel.

g

Fisher's exact test comparing HPV18/45 vs. all other HPV genotyping results.

h

Two‐sample t‐test with unequal variance.

i

Disease stage according to FIGO 2018 [2]. For patients having been re‐staged after surgery, the re‐staged stage is the one listed.

j

Fisher's exact test.